Global Markets Direct’s, 'Epistaxis - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Epistaxis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Epistaxis. Epistaxis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
- A snapshot of the global therapeutic scenario for Epistaxis. - A review of the Epistaxis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Epistaxis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Epistaxis. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Epistaxis pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table Of Contents
Epistaxis - Pipeline Review, H1 2013 Table of Contents 2 List of Tables 3 List of Figures 3 Introduction 4 Global Markets Direct Report Coverage 4 Epistaxis Overview 5 Therapeutics Development 6 An Overview of Pipeline Products for Epistaxis 6 Epistaxis Therapeutics under Investigation by Universities/Institutes 8 Mid Clinical Stage Products 9 Comparative Analysis 9 Epistaxis Therapeutics - Products under Investigation by Universities/Institutes 10 Epistaxis - Therapeutics Assessment 11 Assessment by Monotherapy Products 11 Assessment by Route of Administration 12 Assessment by Molecule Type 14 Drug Profiles 16 estriol - Drug Profile 16 Product Description 16 Mechanism of Action 16 RandD Progress 16 bevacizumab - Drug Profile 17 Product Description 17 Mechanism of Action 17 RandD Progress 17 Epistaxis Therapeutics - Dormant Products 18 Appendix 19 Methodology 19 Coverage 19 Secondary Research 19 Primary Research 19 Expert Panel Validation 19 Contact Us 20 Disclaimer 20
List of Tables
Number of Products Under Development for Epistaxis, H1 2013 6 Products under Development for Epistaxis - Comparative Analysis, H1 2013 7 Number of Products under Investigation by Universities/Institutes, H1 2013 8 Comparative Analysis by Mid Clinical Stage Development, H1 2013 9 Products under Investigation by Universities/Institutes, H1 2013 10 Assessment by Monotherapy Products, H1 2013 11 Assessment by Stage and Route of Administration, H1 2013 13 Assessment by Stage and Molecule Type, H1 2013 15 Epistaxis Therapeutics - Dormant Products 18
List of Figures
Number of Products under Development for Epistaxis, H1 2013 6 Products under Development for Epistaxis - Comparative Analysis, H1 2013 7 Products under Investigation by Universities/Institutes, H1 2013 8 Mid Clinical Stage Products, H1 2013 9 Assessment by Monotherapy Products, H1 2013 11 Assessment by Route of Administration, H1 2013 12 Assessment by Stage and Route of Administration, H1 2013 13 Assessment by Molecule Type, H1 2013 14 Assessment by Stage and Molecule Type, H1 2013 15